C5a modulation of interleukin-1β-induced interleukin-6 production by human osteoblast-like cells

Journal of Periodontal Research

Volumn 35, Issue 3, 2000, Pages 137-145

  Pobanz, John M ^a   Reinhardt, Richard A ^a   Koka, Sreenivas ^a   Sanderson, Sam D ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cell surface molecules; Complement; Cytokines; Osteoblasts

Indexed keywords

AUTACOID; COMPLEMENT COMPONENT C5A; COMPLEMENT RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 6;

ANALYSIS OF VARIANCE; ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; IMMUNOLOGY; METABOLISM; MULTIVARIATE ANALYSIS; OSTEOBLAST; OSTEOLYSIS; PHYSIOLOGY; PROTEIN BINDING; REGRESSION ANALYSIS;

ALVEOLAR BONE LOSS; ANALYSIS OF VARIANCE; COMPLEMENT C5A; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-6; MULTIVARIATE ANALYSIS; OSTEOBLASTS; PROTEIN BINDING; RECEPTORS, COMPLEMENT; REGRESSION ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0034202557     PISSN: 00223484     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0765.2000.035003137.x     Document Type: Article

References (50)

1. Thompson BM, Mundy GR, Chambers TJ. Tumor necrosis factors α and β induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol 1987;138:775-779.
2. Pfeilschifter J, Chenu C, Bird A, Mundy GR, Roodman GD. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclast-like cells in vitro. J Bone Miner Res 1989;4:113-118.
3. Suda T, Takahashi N, Martin TJ. Modulation of osteoclastic differentiation. Endocr Rev 1992;13:66-80.
4. Mundy GR. Inflammatory mediators and the destruction of bone. J Periodont Res 1991;26:213-217.
5. Kimble RB, Vannice JL, Bloedow C et al. IL-1 receptor antagonists decreases bone loss and bone resorption in ovarectomized rats. J Clin Invest 1994;93:1959-1967.
6. Ishmi Y, Miyaura C, Jin CH et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990; 145:3297-3303.
7. Girasole G, Jilka RL, Passeri G et al. 17-β-estadiol inhibits IL-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992;89:883-891.
8. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305-311.
9. Raisz LG, Sandberg AL, Goodson JM, Simmons HA, Mergenhagen SE. Complement-dependent stimulation of prostaglandin synthesis and bone resorption. Science 1974; 185:789-791.
10. Niekrash CE, Patters MR. Assessment of complement cleavage in gingival fluid in humans with and without periodontal disease. J Periodont Res 1986;21:232-242.
11. Hugli TE, Muller-Eberhard HJ. Anaphylatoxins C3a and C5a. Adv Immunol 1978;26:1-53.
12. Fernandez HN, Henson PM, Otani A, Hugli TE. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under simulated in vivo conditions. J Immunol 1978;120:109-115.
13. Shin HS, Snyderman E, Friedman A, Mellors A, Meyer MM. Chemotactic and anaphylactic fragments cleaved from the fifth component of guinea-pig complement. Science 1968;163:361-362.
14. Hugli TE. The structural basis for anaphylatoxins and chemotactic functions of C3a and C5a. Crit Rev Immunol 1981;114:321-366.
15. Goldstein IM, Weissmann G. Generation of C5a-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J Immunol 1974;113:1583-1588.
16. Scholz W, McClurg MR, Cardenas GJ et al. C5a-mediated release of interleukin-6 by human monocytes. Clin Immunol Immunopathol 1990;57:297-307.
17. Ember JA, Sanderson SD, Hugli TE, Morgan EL. Induction of IL-8 synthesis from monocytes by human C5a anaphylatoxin. Am J Pathol 1994;114:393-403.
18. Hammerschmidt DE. Activation of the complement system and of granulocytes in lung injury: the adult respiratory distress syndrome. Adv Inflamm Res 1984;5: 147-172.
19. Mulligan MS, Schmid E, Beck-Schimmer B et al. Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest 1996;98:503-512.
20. Hopkins P, Melmont HM, Buyon J, Phillips M, Weissmann G, Abramson SB. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1988;31:632-641.
21. Takematsu H, Tagami H. Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin. Arch Dermatol 1993;129:74-80.
22. Bergh K, Iverson OJ, Lysvand H. Surprisingly high levels of anaphylatoxin C5a des arg and extractable from psoriatic scales. Arch Dermatol Res 1993;285:131-136.
23. Ward PA, Zvaifler NJ. Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest 1971;50:606-616.
24. Jose PJ, Moss IK, Maini RN, Williams TJ. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis 1990;46: 747-752.
25. Wingrove JA, DiScipio RG, Chen Z, Potempa J, Travis J, Hugli TE. Activation of complement components C3 and C5 by a cysteine proteinase (Gingipain-1) from Porphyromonas (Bacteroides) gingivalis. J Biol Chem 1992;267: 18902-18907.
26. Reinhardt RA, Masada MP, Johnson GK, Dubois LM, Seymour GJ, Allison AC. IL-1 in gingival crevicular fluid following closed root planing and papillary flap debridement. J Clin Periodontol 1993;20:514-519.
27. Morgan EL, Ember JA, Sanderson SD et al. Anti-C5a receptor antibodies: characterization of neutralizing antibodies specific for a peptide, C5aR (9-29), derived from the predicted amino-terminal sequence of the human CSa receptor. J Immunol 1993;151:377-388.
28. SPSS/X users guide. Chicago: SPSS Inc. 1988:568.
29. Stashenko P, Jandinski JJ, Fujiyoshi P, Rynar J, Socransky SS. Tissue levels of bone resorptive cytokines in periodontal disease. J Periodontol 1991;62:504-509.
30. Mannami K, Mitshuhashi T, Takeshita T, Okada K. Concentration of interleukin-1β in serum and synovial fluid in patients with rheumatoid arthritis and those with osteoarthritis. J Jpn Orthop Assoc 1989;63:1343-1352.
31. Okusawa S, Yancey KB, van der Meer JWM et al. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. J Exp Med 1998;168: 443-448.
32. Kishimoto T. The biology of interleukin-6. Blood 1989; 74:1-10.
33. Floreani AA, Heires AJ, Welniak LA et al. Expression of receptors for C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke. J Immunol 1998; 160:5073-5081.
34. Huey R, Hugli TE. Characterization of a C5a receptor on human polymorphonuclear leukocytes (PMN). J Immunol 1985;135:2063-2067.
35. Haviland DL, McCoy RL, Whitehead WT et al. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J Immunol 1995;154:1861-1869.
36. Boulay F, Mery L, Tardiff M, Brouchon L, Vignais P. Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. Biochemistry 1991;30:2993-2998.
37. Chenoweth DE, Hugli TE. Demonstration of a specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1978;75:3943-3951.
38. Bird TA, Saklatvala J. Identification of a common class of high affinity receptors for both types of porcine interleukin-1 on connective tissue cells. Nature 1986;324:263-266.
39. 3. J Clin Invest 1993;91:1731-1742.
40. Shen V, Cheng S, Kohler NG, Peck WA. Characterization and hormonal modulation of IL-1 binding in neonatal mouse osteoblastlike cells. J Bone Miner Res 1990;5: 507-515.
41. Fayyazi A, Sandau R, Duong LQ et al. C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells. Am J Pathol 1999;154:495-501.
42. Sayah S, Ischenko AM, Zhakov A, Bonnard AS, Fontaine M. Expression of cytokines by human astrocytomas following stimulation by C3a and C5a anaphylatoxins: specific increase in interleukin-6 mRNA expression. J Neurochem 1999;72:2426-2436.
43. Pan ZK. Anaphylatoxins C5a and C3a induce nuclear factor kappaB activation in human peripheral blood monocytes. Biochem Biophys Acta 1998;1443:90-98.
44. Langkabel P, Zwirner J, Oppermann M. Ligand-induced phosphorylation of anaphylatoxin receptors C3aR and C5aR is mediated by G-protein-coupled receptor kinases. Eur J Immunol 1999;29:3035-3046.
45. Kuroki M, O'Flaherty JT. Extracellular signal-related protein kinase (ERK)-dependent and ERK-independent pathways target STAT3 on serine-727 in human neutrophils stimulated with chemotactic factors and cytokines. Biochem J 1999;341:691-696.
46. Wilmer WA, Kaumaya PT, Ember JA, Cosio FG. Receptors for the anaphylatoxin C5a (CD88) on human mesangial cells. J Immunol 1998;160:5646-5652.
47. Hsu MH, Wang M, Browning DD, Mukaida N, Ye RD. NF-kappaB activation is required for C5a-induced interleukin-8 gene expression in mononuclear cells. Blood 1999; 93:3241-3249.
48. Van Dyke TE, Lester MA, Shapira L. The role of the host response in periodontal disease progression: implications for future treatment strategies. J Periodontol 1993;64: 792-806.
49. Reinhardt RA, Masada MP, Kaldahl WB et al. Gingival fluid IL-1 and IL-6 levels in refractory periodontitis. J Clin Periodontol 1993;20:225-231.
50. Holt I, Cooper RG, Hopkins SJ. Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Invest 1991;21:479-484.